Utility of [18 F]FLT-PET to Assess Treatment Response in Trastuzumab-Resistant and Trastuzumab-Sensitive HER2-Overexpressing Human Breast Cancer Xenografts

Molecular Imaging and Biology

Volumn 17, Issue 1, 2015, Pages 119-128

  Whisenant, Jennifer G ^a   McIntyre, J Oliver ^a,b   Peterson, Todd E ^a   Kang, Hakmook ^a   Sánchez, Violeta ^d   Manning, H Charles ^a,c,d   Arteaga, Carlos L ^a,b   Yankeelov, Thomas E ^a,b,c,d  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Assessing treatment response; Breast cancer; HER2+ xenografts; Trastuzumab; 18 F FLT PET

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; DRUG DESIGN; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DIDEOXYNUCLEOSIDES; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939874398     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0770-z     Document Type: Article

References (36)

1. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27:5838–47
2. Dean-Colomb W, Esteva FJ (2008) Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44:2806–12
3. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413–28
4. Murphy CG, Morris PG (2012) Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23:765–76
5. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215
6. Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285–9
7. Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676–85
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–72
9. Piccart M (2008) Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin Breast Cancer 8(Suppl 3):S100–13
10. Seidman AD, Fornier MN, Esteva FJ et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587–95
11. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–92
12. Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800–8
13. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–84
14. Neve RM, Holbro T, Hynes NE (2002) Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 21:4567–76
15. Dunphy MP, Lewis JS (2009) Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50(Suppl 1):106S–21S
16. 18 F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. J Nucl Med 54:424–30
17. Mason NS, Lopresti BJ, Ruszkiewicz J et al (2013) Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. Am J Nucl Med Mol Imaging 3:16–31
18. 18 F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 51:1559–64
19. 18 F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 54:532–40
20. Kahraman D, Holstein A, Scheffler M et al (2012) Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med 37:1058–64
21. McKinley ET, Ayers GD, Smith RA et al (2013) Limits of [(18)F]-FLT PET as a Biomarker of Proliferation in Oncology. PLoS One 8:e58938
22. 18 F]fluorothymidine imaging. Clin Cancer Res 17:1099–110
23. Monazzam A, Razifar P, Ide S et al (2009) Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nucl Med Biol 36:335–42
24. Shah C, Miller TW, Wyatt SK et al (2009) Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15:4712–21
25. Ritter CA, Perez-Torres M, Rinehart C et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909–19
26. 18 F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32:653–9
27. Manning HC, Merchant NB, Foutch AC et al (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14:7413–22
28. Tai YC, Ruangma A, Rowland D et al (2005) Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 46:455–63
29. Qi J, Leahy RM, Cherry SR, Chatziioannou A, Farquhar TH (1998) High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. Phys Med Biol 43:1001–13
30. Oyama N, Ponde DE, Dence C et al (2004) Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45:519–25
31. Harrell F. Resampling, validating, describing, and simplifying the model. In: Springer, editor. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2001. p. 87–104.
32. Cullinane C, Waldeck KL, Binns D et al (2014) Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. Nucl Med Biol 41:148–54
33. Mankoff DA, Shields AF, Krohn KA (2005) PET imaging of cellular proliferation. Radiol Clin North Am 43:153–67
34. Krohn KA, Mankoff DA, Eary JF. (2001) Imaging cellular proliferation as a measure of response to therapy. Journal of clinical pharmacology Suppl:96S-103S.
35. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–19
36. Miller TW, Forbes JT, Shah C et al (2009) Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15:7266–76